Avedro Reaches Reimbursement Milestone for Its FDA-Approved

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
30
Avedro Reaches Reimbursement Milestone for Its FDA-Approved Procedure for Progressive Keratoconus

WALTHAM, Mass., April 05, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc ., (Avedro or the company), today announced that four new providers --Providence Health Plan in the Pacific Northwest, Health New England, HealthPartners Minnesota and Public Employees Health Plan (PEHP) in Utah--have issued positive coverage policies for Avedro’s FDA-approved corneal cross-linking procedure, bringing the total number of commercial plans covering the KXL system and its associated Photrexa® drug formulations to over 65. These four plans bring the total number of covered lives in the United States to more than 180 million.

Keratoconus is a debilitating and typically progressive eye disease that can lead to loss of vision and even blindness. Avedro’s KXL system and associated Photrexa ® drug formulations have been approved by the FDA as a one-time treatment that can slow or halt the progression of the disease, potentially eliminating the need for invasive procedures such as corneal transplant.

In addition, Avedro has secured positive coverage from the United States’ largest national commercial payers, including United Healthcare, Anthem Blue Cross Blue Shield, Aetna, Cigna, Humana, and HealthNet. The company estimates that more than 95% of commercially covered lives have access to the Avedro’s potentially sight-saving technology.

“We are very pleased to see that in just one year, access has rapidly and dramatically improved for patients needing therapeutic treatment for progressive keratoconus,” said Reza Zadno, Ph.D., Chief Executive Officer of Avedro. "In addition to securing coverage from our country’s top commercial payers, we’ve received a unique J-code from CMS. This is in large part due to the amazing support and hard work of the societies, doctors and patient advocacy groups who see and hear from patients daily. Avedro will continue to invest in reimbursement services to ensure corneal cross-linking is accessible to patients struggling with progressive keratoconus.”

Patients can find the list of private payer insurance companies providing coverage for corneal cross-linking at LivingwithKeratoconus.com .

About Avedro, Inc.

Avedro is a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Avedro’s proprietary Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. The Avedro Corneal Remodeling Platform is comprised of Avedro’s KXL and Mosaic systems, each of which delivers ultraviolet A light, and a suite of proprietary single-use riboflavin drug formulations, which, when applied together to the cornea, induce a biochemical reaction called corneal collagen cross-linking.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but are not limited to, statements about the market opportunity for the Avedro Corneal Remodeling Platform and the rate of adoption of FDA approved cross-linking procedures. Words such as “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of risks and uncertainties and other important factors, any of which could cause Avedro’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Avedro’s annual report on Form 10-K filed March 21, 2019 as well as discussions of potential risks, uncertainties and other important factors in Avedro’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Avedro undertakes no duty to update this information unless required by law.

IMPORTANT SAFETY INFORMATION

INDICATIONS Photrexa ® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa ® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking (CXL) for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

LIMITATIONS OF USE The safety and effectiveness of CXL have not been established in pregnant women, women who are breastfeeding, patients who are less than 14 years of age and patients 65 years of age or older. Photrexa Viscous and Photrexa should be used with the KXL System only.

WARNINGS AND PRECAUTIONS Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.

ADVERSE REACTIONS In progressive keratoconus patients, the most common ocular adverse reactions in any CXL treated eye were corneal opacity (haze), punctate keratitis, corneal striae, corneal epithelium defect, eye pain, reduced visual acuity, and blurred vision. In corneal ectasia patients, the most common ocular adverse reactions were corneal opacity (haze), corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, photophobia, reduced visual acuity, and blurred vision. 

These are not all of the side effects of Photrexa ® Viscous, Photrexa ® and the CXL treatment. For more information, see Prescribing Information .

You may report an adverse event to Avedro by calling 1-844-528-3376, Option 1 or you may contact the U.S. Food and Drug Administration (FDA) directly at 1-800-FDA-1088.

Avedro Contact :   Investor Contact:
David Iannetta   Greg Chodaczek or Lynn Lewis
Avedro, Inc.   Phone:  646-924-1769
(781) 768-3400   investors@avedro.com
info@avedro.com    
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 128

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 154

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 68

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 65

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 63

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading

Top 5 Most Recently Viewed Articles

Radiant Striping's Community Commitment through Service Initiatives

Updated Category News Views 144

Radiant Striping's Charitable Impact on the Community Radiant Striping, a veteran-owned company, is making waves in their community through generous donations of parking lot striping and other services to local organizations. It's not just about the perfect paint job; it’s about building safer, more welcoming spaces for families and visitors alike. A Mission Rooted in...

Continue Reading
Supernus Pharmaceuticals Announces Participation in Key Healthcare Event

Updated Category News Views 86

Supernus Pharmaceuticals' Participation in the Healthcare Conference Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dedicated biopharmaceutical company, is excited to announce its upcoming participation in a significant healthcare conference. The conference will take place soon, and prominent figures from the company, including Jack Khattar, President and CEO, are set...

Continue Reading
CTC Celebrated as Top Veteran-Friendly Employer in 2024

Updated Category News Views 70

Concurrent Technologies Corporation Recognized in 2024 Concurrent Technologies Corporation (CTC) is thrilled to announce its inclusion in the U.S. Veterans Magazine’s Top Veteran-Friendly Employers list for 2024. This achievement marks the fourth consecutive year that CTC has received this important recognition. How U.S. Veterans Magazine Evaluates Employers Each year,...

Continue Reading
Chimerix Announces Inducement Grant of Stock Options

Updated Category News Views 188

Chimerix Announces Inducement Grant of Stock Options Chimerix (NASDAQ:CMRX), a prominent biopharmaceutical company, has announced a notable inducement award for a newly hired employee. This grant includes non-statutory stock options totaling 150,000 shares of the company's common stock, underscoring Chimerix's dedication to attracting top talent in the competitive biotech...

Continue Reading
EarFun Showcases Cutting-Edge Wireless Audio Innovations

Updated Category News Views 620

Discover the Latest Innovations from EarFun at CES 2025 EarFun, a prominent name in wireless audio technology, is set to unveil a range of cutting-edge products that will redefine the audio experience. Their participation in CES 2025 promises to highlight significant advancements that cater to diverse listening needs. Innovative AI-Powered Features The spotlight will be...

Continue Reading